Patten Group Inc. Makes New $215,000 Investment in Masimo Co. (NASDAQ:MASI)

Patten Group Inc. purchased a new position in shares of Masimo Co. (NASDAQ:MASI) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,360 shares of the medical equipment provider’s stock, valued at approximately $215,000.

Several other large investors also recently bought and sold shares of MASI. Invesco Ltd. increased its position in shares of Masimo by 126.3% during the 2nd quarter. Invesco Ltd. now owns 1,235,508 shares of the medical equipment provider’s stock worth $183,868,000 after purchasing an additional 689,534 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Masimo by 547.3% during the 3rd quarter. Eagle Asset Management Inc. now owns 476,985 shares of the medical equipment provider’s stock worth $70,970,000 after purchasing an additional 403,292 shares during the last quarter. Carillon Tower Advisers Inc. increased its position in shares of Masimo by 189.1% during the 3rd quarter. Carillon Tower Advisers Inc. now owns 460,109 shares of the medical equipment provider’s stock worth $68,459,000 after purchasing an additional 300,934 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in shares of Masimo during the 2nd quarter worth approximately $25,921,000. Finally, Handelsbanken Fonder AB increased its position in shares of Masimo by 69.7% during the 3rd quarter. Handelsbanken Fonder AB now owns 226,500 shares of the medical equipment provider’s stock worth $33,701,000 after purchasing an additional 93,000 shares during the last quarter. 82.71% of the stock is currently owned by hedge funds and other institutional investors.

MASI stock opened at $164.03 on Wednesday. The firm has a market capitalization of $8.68 billion, a PE ratio of 54.14, a PEG ratio of 2.02 and a beta of 1.13. Masimo Co. has a 1-year low of $111.33 and a 1-year high of $165.48. The business’s 50 day simple moving average is $157.98 and its 200 day simple moving average is $152.03.

Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. The business had revenue of $229.01 million for the quarter, compared to analyst estimates of $221.92 million. Masimo had a return on equity of 17.32% and a net margin of 20.83%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.71 EPS. As a group, research analysts predict that Masimo Co. will post 3.17 EPS for the current fiscal year.

In other Masimo news, EVP Thomas Samuel Mcclenahan sold 500 shares of the company’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $159.29, for a total value of $79,645.00. Following the transaction, the executive vice president now directly owns 5,607 shares of the company’s stock, valued at approximately $893,139.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Yongsam Lee sold 24,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $156.84, for a total value of $3,764,160.00. Following the completion of the transaction, the executive vice president now directly owns 97,000 shares in the company, valued at $15,213,480. The disclosure for this sale can be found here. Insiders have sold a total of 56,000 shares of company stock worth $8,683,715 over the last three months. 11.50% of the stock is owned by insiders.

MASI has been the topic of several recent analyst reports. BidaskClub raised Masimo from a “hold” rating to a “buy” rating in a research report on Monday, December 16th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $175.00 price target (up previously from $161.00) on shares of Masimo in a research report on Tuesday, December 17th. Finally, ValuEngine lowered Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $161.75.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: Which market index is the best?

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit